Cell and gene therapies (CGT), also known as advanced therapy medicinal products (ATMPs) in the EU, are a class of products based on genes, tissues or cells that can benefit patients with debilitating or life-shortening diseases. Most CGTs are “living” therapies, with highly complex manufacturing processes and unclear mechanisms of action. In addition, these therapies are characterised by variable starting materials, short shelf lives and small sample sizes. They may also pose unique risks such as immunogenicity, tumorigenicity, microbiological purity and variable efficacy.
Due to their unique qualities and risks, CGTs require specific regulatory requirements and guidelines. Additional, more targeted regulations are required for the subset of CGTs that harness replicating viral vectors, which carry potential transmission risks. These guidances are updated regularly to account for our evolving understanding of CGTs and CGT manufacturing. Several changes to two key regulatory guidance documents for CGTs were released by the U.S. Food and Drug Administration (FDA) in January 2020, and are summarised below.
Updated FDA guidance: Chemistry, Manufacturing and Control Information for Human Gene Therapy Investigational New Drugs
Updates to this guidance supersede the previous one published in 2008, and describe what information is required to assure product safety, quality and purity. It applies to human CGTs and therapeutics that contain a human gene therapy in combination with a drug or device. Key changes include:
- Expansion of required safety information regarding reagents used in manufacturing, specifically reagents of biological origin that increase the risk of introducing unintended agents in the final product.
- Recommendations on the characterisation of cell lines used in the manufacture of monoclonal antibodies and product testing requirements for antibodies, including those used as ancillary products.
- Updated recommendations for the derivation, testing and reporting of plasmids used as intermediates in the manufacturing of CGTs, specifically adeno-associated viruses and lentiviral vectors.
- Additional detail on the characterisation of product- and process-related drug substance impurities, and recommendations for manufacturing optimisations to minimise the level of impurities present in final CGT products.
Updated FDA guidance: Testing of Retroviral Vector-based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up
Vector-based human gene therapy products must undergo testing to ensure they exclude the potentially pathogenic replication competent retrovirus (RCR), historically referred to as the replication competent lentivirus (RCL). The 2020 guidance supersedes the guidance from 2006, and provides updated recommendations on testing for RCR during the manufacture, follow-up and monitoring of gene therapy products derived from the Retroviridae family of viruses. As per this guidance:
- Cells and the supernatant from the master cell bank production should still be tested for RCR. However, working cell banks, from a master cell bank that tested negative for RCR, no longer need to be tested.
- All transduced cells, which are modified through retrovirus or lentivirus transduction, should be tested for RCR, regardless of the time in culture. This is a change from the previous guidance, which recommended RCR testing only for transduced cells cultured longer than four days.
- Appropriate, accumulated manufacturing and clinical data of RCR-negative transduced cell products may be provided to the FDA to reduce or eliminate RCR testing. If the FDA supports the reduction or elimination of testing, the archival of cell products for future RCR testing is recommended.
- Testing 5 percent of the total production volume in the RCR assay is still recommended. While the prior guidance permitted an alternative testing volume of 300 mL for production volumes that exceed 6 L, this volume may be insufficient to detect one RCR per dose given current manufacturing practices. For production volumes that exceed 6 L, new guidance outlines how to conduct testing that will ensure a 95 percent probability of detecting one RCR per dose.
To date, 47 cell therapy and 23 gene therapy products have been approved. As knowledge of CGTs and CGT manufacturing increases, appropriate guidance from regulatory agencies will be critical to the continued growth of the industry. Therapeutic developers may benefit from working with a partner whose regulatory expertise with CGTs will help ensure that development programmes are optimal and compliant, despite evolving global and regional regulatory requirements.
In this section
-
Digital Disruption
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel